These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 16990197

  • 1. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
    Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N, ROSE Trial Investigators.
    Scand J Gastroenterol; 2006 Oct; 41(10):1132-40. PubMed ID: 16990197
    [Abstract] [Full Text] [Related]

  • 2. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G, Italian Rabeprazole Study Group.
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [Abstract] [Full Text] [Related]

  • 3. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
    Archimandritis AJ, Nikolopoulou V, Kouklakis G, Paraskevas E, Avgerinos A, Tsianos E, Triantafillidis JK, Hellenic Rabeprazole Study Group.
    Curr Med Res Opin; 2005 Apr; 21(4):603-10. PubMed ID: 15899110
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
    Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL.
    Aliment Pharmacol Ther; 2002 Mar; 16(3):479-85. PubMed ID: 11876701
    [Abstract] [Full Text] [Related]

  • 5. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators.
    Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
    [Abstract] [Full Text] [Related]

  • 6. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
    Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S.
    Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
    [Abstract] [Full Text] [Related]

  • 7. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A, Breiter J, Perdomo C, Barth J.
    Aliment Pharmacol Ther; 2005 Aug 01; 22(3):193-202. PubMed ID: 16091056
    [Abstract] [Full Text] [Related]

  • 8. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
    Delchier JC, Cohen G, Humphries TJ.
    Scand J Gastroenterol; 2000 Dec 01; 35(12):1245-50. PubMed ID: 11199361
    [Abstract] [Full Text] [Related]

  • 9. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P, van Zanten SV, Mattsson H, Wernersson B.
    Aliment Pharmacol Ther; 2012 Oct 01; 36(7):635-43. PubMed ID: 22860764
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
    Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalväg A, Junghard O, Wiklund I.
    Eur J Gastroenterol Hepatol; 1998 Feb 01; 10(2):119-24. PubMed ID: 9581986
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
    Bytzer P, Blum A, De Herdt D, Dubois D, Trial Investigators.
    Aliment Pharmacol Ther; 2004 Jul 15; 20(2):181-8. PubMed ID: 15233698
    [Abstract] [Full Text] [Related]

  • 18. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ.
    Aliment Pharmacol Ther; 1999 Jan 15; 13(1):49-57. PubMed ID: 9892879
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.